|
|
Post by notamnkdmillionaire on Aug 13, 2015 18:51:34 GMT -5
We try to keep it nice in here. If not there are very powerful folks who will lock down the post. I like it here much better and don't spend much time on the other boards at all. They might even lock you down for using the unflattering pic of Tom Brady!  |
|
|
|
Post by jay1ajay1a on Aug 13, 2015 19:57:43 GMT -5
We try to keep it nice in here. If not there are very powerful folks who will lock down the post. I like it here much better and don't spend much time on the other boards at all. They might even lock you down for using the unflattering pic of Tom Brady! I like it, and it better then my photo  |
|
|
|
Post by kball on Aug 13, 2015 21:57:20 GMT -5
They might even lock you down for using the unflattering pic of Tom Brady! Looks more like one of those spooky family members on that X-Files episode. |
|
|
|
Post by mssciguy on Oct 16, 2015 10:00:42 GMT -5
|
|
|
|
Post by falconquest on Oct 17, 2015 6:37:28 GMT -5
The word "aerosol" in the description of the Monash University product indicates that it is not Technosphere technology they're using. |
|
|
|
Post by rockstarrick on Oct 17, 2015 10:39:09 GMT -5
Forgive me but I am a bit confused. We heard a while back about Monash University and their inhaled oxytocin. Some believed it was Mannkind who was behind the tech but review of their info seemed to conclude they were using the tech that Pfizer used from their purchase of Nektar. Yes, the same failed tech found in Exubera. Yesterday, Hakan (gotta be one of the most uninspiring CEOs I have ever heard) mentioned this: At first I thought he was talking about Monash (since Mintaka starts with a "M" I was thinking he was talking about Monash and thought, "WHOA, I was wrong about my initial critique of those saying Mannkind was involved with 'that company' Monash." Well, I wasn't wrong as this is a totally different foundation. But the question remains, why has Mannkind been so quiet about this? One other note, I searched The Gates Foundation website and found no mention of Mintaka. www.mintakafoundation.org/our-projects/maternal-health/http://www.google.com/patents/WO2013016754A1?cl=enhttp://www.google.com/patents/WO2013016754A1?cl=en |
|
|
|
Post by rockstarrick on Oct 17, 2015 10:41:25 GMT -5
|
|
|
|
Post by rockstarrick on Oct 17, 2015 10:43:09 GMT -5
And enter Mannkind The particles may be obtained and engineered into any known particle engineering system, such as but not limited by the following: Pulmosphere™ or Pulmosol™ technology developed by Nektar, AIR™ porous particle technology develed by Alkermes, Technosphere™ technology developed by Mannkind, Powderhale™ technology developed by Vectura, particles created by Prosonix sonocrystalisation methods, particles created by wet or dry nano-milling technologies for example developed by Elan, Hovione or Savara. |
|
|
|
Post by rockstarrick on Oct 17, 2015 10:45:01 GMT -5
And enter Mannkind The particles may be obtained and engineered into any known particle engineering system, such as but not limited by the following: Pulmosphere™ or Pulmosol™ technology developed by Nektar, AIR™ porous particle technology develed by Alkermes, Technosphere™ technology developed by Mannkind, Powderhale™ technology developed by Vectura, particles created by Prosonix sonocrystalisation methods, particles created by wet or dry nano-milling technologies for example developed by Elan, Hovione or Savara. Comments ?? Thanks |
|
|
|
Post by falconquest on Oct 18, 2015 8:30:30 GMT -5
And enter Mannkind The particles may be obtained and engineered into any known particle engineering system, such as but not limited by the following: Pulmosphere™ or Pulmosol™ technology developed by Nektar, AIR™ porous particle technology develed by Alkermes, Technosphere™ technology developed by Mannkind, Powderhale™ technology developed by Vectura, particles created by Prosonix sonocrystalisation methods, particles created by wet or dry nano-milling technologies for example developed by Elan, Hovione or Savara. Comments ?? Thanks Not trying to challenge you rock but rather to clarify. The definition of an aerosol is a "substance enclosed under pressure". Not that Technosphere could not be used in such an application but we certainly haven't seen it before. "Pulmonary delivery has been proposed to be a suitable systemic route for biological agents such as peptides, proteins, vaccines, and nucleic acid based agents. The challenges in delivering such large macromolecules are substantial and result in a broad and major uncertainty and risk as to the possibility of success. The challenges begin with the generation of an aerosol of appropriate dose which is suitable for efficient and consistent deep lung delivery". |
|
|
|
Post by rockstarrick on Oct 18, 2015 12:00:16 GMT -5
The portion of the article I shared is just a list of options "particle engineering systems",(Approved Drug Delivery Systems) available for Companies looking to develop an inhalation portfolio, and Mannkinds Technosphere is listed as one of them. There is another article I found about The future and Market of inhaled drugs, I only glanced at it, but it does talk about newer Technology that doesn't require a propellant. It seemed to me that this thread was started due to a question about Mannkind being, or not being involved with Monash Inhaled Oxytocin funded by The Gates Foundation. I believe the article clearly shows any of the "Approved Paticle Engineering Systems" listed, could be selected by Monash. I'm not claiming Mannkind will be the choice of Monash, but it could be. Here is another interesting article about Inhalation. capsugel.com/media/library/DPI_White_Paper_FINAL_Web.pdfWith the Inhaled Drug Market to reach "37 Billion dollars in the next 5 years", I feel confident Mannkind and Technosphere will capture at least some of this market, and I also believe the possibility is there for Mannkind to work with the Monash project funded by The Gates Foundation. Just My Opinion. Good Luck To All |
|
|
|
Post by rockstarrick on Oct 18, 2015 12:05:03 GMT -5
The portion of the article I shared is just a list of options "particle engineering systems",(Approved Drug Delivery Systems) available for Companies looking to develop an inhalation portfolio, and Mannkinds Technosphere is listed as one of them. There is another article I found about The future and Market of inhaled drugs, I only glanced at it, but it does talk about newer Technology that doesn't require a propellant. It seemed to me that this thread was started due to a question about Mannkind being, or not being involved with Monash Inhaled Oxytocin funded by The Gates Foundation. I believe the article clearly shows any of the "Approved Paticle Engineering Systems" listed, could be selected by Monash. I'm not claiming Mannkind will be the choice of Monash, but it could be. Here is another interesting article about Inhalation. capsugel.com/media/library/DPI_White_Paper_FINAL_Web.pdfWith the Inhaled Drug Market to reach "37 Billion dollars in the next 5 years", I feel confident Mannkind and Technosphere will capture at least some of this market, and I also believe the possibility is there for Mannkind to work with the Monash project funded by The Gates Foundation. Just My Opinion. Good Luck To All The global market for pulmonary drug delivery is growing rapidly and is expected to reach US $37.7 billion within the next five years with the US and Europe accounting for 75% share. There is a move away from the traditional MDIs towards newer, more sophisticated DPIs reflecting the increased research into powder formulations and innovations in particle engineering.8 Capsule-based devices in particular, offer many benefits to patients in terms of precise dosing, ease of use and dose visibility. The devices are hygienic to use and simple to clean and are presented in attractive designs. |
|
|
|
Post by fofos2000i on Jun 9, 2016 8:29:37 GMT -5
New patent on Oxytocin HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS www.freepatentsonline.com/y2016/0158156.htmlA:Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, OTHER ROUTES of administration can be used when reconstituted in solution. |
|
|
|
Post by wmdhunt on Jun 9, 2016 9:56:17 GMT -5
This patent is fantastic. HooRay for Mannkind. Hope it works out. If it does, it is a lock on wonderful things to come.
|
|
|
|
Post by jay1ajay1a on Jun 9, 2016 11:33:26 GMT -5
I like this!
|
|
